You are here: Industry Insights > CureVac

News List

CureVac works on mRNA vaccine for coronavirus pharmaceutical-technology
March 17, 2020
German biopharmaceutical company CureVac is working on the development of an mRNA-based vaccine to protect against Covid-19 coronavirus infection.
Genmab, CureVac Enter Partnership to Develop mRNA-based Antibody Therapeutics americanpharmaceuticalreview
December 23, 2019
Genmab and CureVac have entered into a research collaboration and license agreement. This strategic partnership will focus on the research and development of ...
CureVac collaborates with Yale for mRNA-based pulmonary therapeutics biospectrumasia
August 18, 2019
The exclusive CRA covers the development of an undisclosed number of novel mRNA-based candidates for pulmonary diseases.
CureVac and Yale University to develop mRNA-based lung therapies pharmaceutical-technology
August 15, 2019
Biopharmaceutical firm CureVac has signed a collaborative research agreement with US-based Yale University to discover new therapeutic candidates for the treatment of pulmonary diseases.
CureVac, Yale Collaborate on Discovery Research contractpharma
August 14, 2019
Will focus on developing novel mRNA-based candidates for pulmonary diseases.
Lilly, CureVac pen $1.8B mRNA cancer vaccine deal fiercebiotech
October 19, 2017
Lilly is making a $50 million upfront payment and €45 million equity investment to get the deal up and running.

Previous page 1 2 3 4 5 Next page